Physician profile
Grace Chang
NPI 1508144783
$1,617.74
in general payments reported to CMS, 2019-2025
13 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2021: $189 · 2022: $383 · 2023: $65.83 · 2024: $435 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.20 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $236.85 | 2024 | Opdivo |
| Inari Medical, INC. | $191.92 | 2022 | |
| Janssen Biotech, INC. | $189.00 | 2021 | |
| Rigel Pharmaceuticals, INC. | $168.09 | 2025 | Rezlidhia, Gavreto, Tavalisse |
| Merck Sharp & Dohme LLC | $165.22 | 2019-2023 | Lynparza, Keytruda |
| Genentech USA, INC. | $149.04 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $133.32 | 2025 | Onivyde |
| Incyte Corporation | $125.92 | 2025 | Monjuvi |
| Blueprint Medicines Corporation | $104.90 | 2024 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $93.29 | 2024 | |
| Pfizer INC. | $25.00 | 2023 | |
| Beigene USA, INC. | $17.66 | 2023 | Brukinsa |
| Eisai INC. | $17.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.